Predictions of cisplatin-induced hyponatremia in patients with malignancy: a retrospective cohort survey of all cisplatin administration in clinical practice.

Authors

Yuki Nagashima, Satoru Muto, Yosuke Shimada, Shigeo Horie

Published in

Clinical and experimental nephrology. Jul 24, 2026. Epub Jul 24, 2026.

Abstract

Despite the rise of cancer immunotherapy, cisplatin remains a cornerstone in chemotherapy. Hyponatremia is a common but under-recognized adverse event of cisplatin. Previous studies on cisplatin-induced hyponatremia (CIH) are limited and mostly focus on the initial administration. This study aimed to assess the overall incidence of CIH and identify significant predictive factors.
We conducted a single-center, retrospective cohort study of patients who received intravenous cisplatin at Juntendo University Hospital between 2018 and 2020. The occurrence and severity of CIH were assessed across all administrations. Predictive factors were analyzed using multiple logistic regression and generalized linear mixed models.
Among 706 patients, 340 (48.2%) experienced CIH during the study period, with 103 (14.6%) developing Grade 3 or higher severity. Across 1939 total cisplatin administrations, CIH occurred in 585 (30.2%) cases, including 135 (7.0%) with Grade ≥ 3 severity. CIH was most common at first administration (38.8%), with severe cases occurring in 11.9%. Generalized linear mixed models results that the significant prognostic factors for cisplatin-induced Hyponatremia were age (OR: 1.41, p < 0.001), last cisplatin dose (OR: 1.74, p < 0.001), serum albumin (OR: 0.65, p < 0.001), serum sodium (OR: 0.35, p < 0.001), WBC (OR: 1.26, p = 0.01), and concomitant 5-FU administration (OR: 3.91, p < 0.001).
CIH is a frequent and potentially serious complication of cisplatin therapy. Older age, high-dose cisplatin, hypoalbuminemia, hyponatremia, leukocytosis, and 5-FU co-administration significantly increase the risk. These findings highlight the importance of proactive monitoring and management strategies to mitigate CIH risk.

PMID:
42496909
Bibliographic data and abstract were imported from PubMed on 24 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.